MBTA Cuts Ahead: COVID Causes Commuters To Consider Comprehensive Changes

Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Host Joe Selvaggi and Pioneer Institute Senior Fellow Charlie Chieppo discuss the reasons for the recently proposed cuts to MBTA service, and offer suggestions as to how the agency’s leadership could use this crisis to improve the service’s long-term health.

Related: Read Charlie Chieppo & Jim Stergios’ recent op-ed in Commonwealth magazine: “Contracting with private providers could avert MBTA cuts.”

Guest:

Charlie Chieppo is a Pioneer senior fellow. Previously, he was policy director in Massachusetts’ Executive Office for Administration and Finance and directed Pioneer’s Shamie Center for Restructuring Government. While in state government, Charlie led the successful effort to reform the Commonwealth’s public construction laws, helped develop and enact a new charter school funding formula, and worked on state workforce issues such as pension reform and easing state restrictions against privatization. In 2000, Charlie was a member of the MBTA’s Blue Ribbon Committee on Forward Funding and has written and commented extensively on T and other transportation issues. He was a contributor to “MBTA Capital Spending Derailed by Expansion,” by the Massachusetts Taxpayers Foundation with Pioneer Institute, which won the Government Research Association’s “Most Distinguished Research” award. Chieppo is a graduate of Boston University’s College of Communication and Vanderbilt University Law School.

Get new episodes of Hubwonk in your inbox!

Related Posts:

Enduring the Maelstrom: Lessons from MassPort Leadership During 9/11

Hubwonk host Joe Selvaggi talks with author and former MassPort CEO Virginia Buckingham about her recently released book, On My Watch: A Memoir, which chronicles her experience leading the organization through 9/11 and the life and leadership lessons learned from that tragic day.

Rescuing Afghan Refugees: Finding Redemption amidst the Wreckage of Collapse

Hubwonk host Joe Selvaggi talks with Jeffrey Thielman, President and CEO of the International Institute of New England, about the path refugees must take to resettle in the US, how organizations like his facilitate and integrate refugees including those recently displaced in Afghanistan, and what individuals concerned about the fate of refugees can do to support their resettlement. 

Untangling Variants & Outbreaks: Can Vaccines & Natural Immunity Outrun Delta?

Hubwonk host Joe Selvaggi talks with author, surgeon, and public health expert Dr. Marty Makary about the COVID-19 Delta Variant, the durability of natural and vaccinated immunity, the benefits of booster shots, and the health risks for children as we move into the fall.

Targeting Pharma: Infrastructure Bill Employs Price Controls To Offset Unprecedented Price Tag

Hubwonk host Joe Selvaggi talks with Pioneer Institute Visiting Fellow in Life Sciences Dr. William Smith about how the price control features of the emerging $3.5 trillion infrastructure bill might affect the pharmaceutical Industry, both nationwide and here in Massachusetts, and what effect that change will have on drug consumers.

Examining Eviction Moratoriums: Testing Constitutional Limits of Executive Branch Power

Hubwonk host Joe Selvaggi talks with constitutional scholar and George Mason Law Professor Ilya Somin about the flaws and legal vulnerabilities of the first and second CDC eviction moratoriums and discuss what current and future court rulings will mean for the limits of executive agency powers.

Pandemic Pension Payout: Essential COVID-19 Public Workers Rewarded Whether Essential or Working

Hubwonk host Joe Selvaggi talks with Pioneer Institute’s Director of Research and former Massachusetts Inspector General and State Representative Greg Sullivan about HB 2808, COVID-19 Essential Employee Retirement Credit Bonus, discussing the merits of the recently proposed joint bill, its cost, and our current public debt burden in the Commonwealth.

College Debt Explained: Education Pays When Students Choose Wisely

Hubwonk host Joe Selvaggi talks with American Enterprise Institute resident fellow and education economist Beth Akers about the American student debt crisis (totalling $1.6 trillion). They explore who borrows, who is in debt, and which policy choices might best serve the financial needs of every student. 

Chasing Election Integrity: Strict Voter ID Laws’ Impact on Turnout and Fraud

Joe Selvaggi talks with Harvard Business School Professor Vincent Pons about his recently released NBER paper on the effects of strict voter ID laws on voter behavior and fraud across the United States over 10 years, examining the results of the 1.6 billion observation dataset by age, race, gender, and party affiliation.

The Oldest Hatred: Calling Out Antisemitism In Its Many Forms

Hubwonk host Joe Selvaggi talks with Boston Globe opinion writer Jeff Jacoby about the troubling increase in antisemitic incidents, including the recent attack on a Boston rabbi, and how our current political rancor fans the flames of bigotry nationwide.

Court Preserves Privacy: First Amendment Ruling Defends Non-Profits From Modern-Day McCarthyism

Hubwonk Host Joe Selvaggi talks with CATO research fellow and constitutional scholar Trevor Burrus about the recent Supreme Court ruling, Americans For Prosperity Foundation v. Bonta, reaffirming the right to privacy by denying the state of California the right to compel non-profits to disclose their list of donors.

Renters’ Unsung Heroes: Small Landlords Endure Without Income or Relief

Hubwonk host Joe Selvaggi talks with MassLandlords’ Doug Quattrochi about ways landlords faced the challenges of being caught between tenants unable to pay rent during COVID-19 shutdown and having little or no programmatic relief from state and federal agencies.

Alzheimer Breakthrough Disillusionment: Confusion on FDA’s Approval of Expensive and Possibly Ineffective Drug

Hubwonk host Joe Selvaggi talks with precision medicine expert Hannah Mamuszka and Pioneer Institute's Bill Smith about the promises and pitfalls of the newly approved Alzheimer’s drug Aduhelm, and the challenges presented when new, expensive drugs of dubious benefit are introduced to the nation’s formulary.